Cargando…
Physicochemical characterization of Remsima®
Remsima® (infliximab) was recently approved as the world's first biosimilar monoclonal antibody (mAb) in both the European Union and Korea. To achieve this, extensive physicochemical characterization of Remsima® in relation to Remicade® was conducted in order to demonstrate the highly similar p...
Autores principales: | Jung, Soon Kwan, Lee, Kyoung Hoon, Jeon, Jae Won, Lee, Joon Won, Kwon, Byoung Oh, Kim, Yeon Jung, Bae, Jin Soo, Kim, Dong-Il, Lee, Soo Young, Chang, Shin Jae |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622713/ https://www.ncbi.nlm.nih.gov/pubmed/25517302 http://dx.doi.org/10.4161/mabs.32221 |
Ejemplares similares
-
Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®
por: Lee, Changsoo, et al.
Publicado: (2017) -
Evaluation of the physicochemical and functional stability of diluted REMSIMA(®) upon extended storage—A study compliant with NHS (UK) guidance
por: Young, Benjamin L., et al.
Publicado: (2015) -
Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product
por: Lee, Kyoung Hoon, et al.
Publicado: (2018) -
Physicochemical Characterization and Potential Prebiotic Effect of Whey Protein Isolate/Inulin Nano Complex
por: Ha, Ho-Kyung, et al.
Publicado: (2016) -
Comparison of Morphological and Physicochemical Properties of a Floury Rice Variety upon Pre-Harvest Sprouting
por: Han, Chae-Min, et al.
Publicado: (2021)